J. Goldman & Co’s Avidity Biosciences RNAM Stock Holding History

J. Goldman & Co’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-8,039	Closed	-$350K	–	709
2025 Q3	$350K	Buy	+8,039	New	+$325K	0.01%	398

Other funds holding RNAM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

J. Goldman & Co's RNAM Position: Q4 2025 in Review

J. Goldman & Co sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 8,039 shares — an estimated $350K sold.

J. Goldman & Co first reported a position in RNAM in Q3 2025 and held it in 1 quarter. The position peaked at $350K in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

J. Goldman & Co reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
J. Goldman & Co sold 8,039 Avidity Biosciences shares in Q4 2025, an estimated $350K.
J. Goldman & Co first reported a position in Avidity Biosciences in Q3 2025 and held it in 1 quarter.
J. Goldman & Co's Avidity Biosciences position peaked at $350K in Q3 2025.
343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.